Research advances in neoadjuvant therapy for resectable pancreatic cancer
10.3760/cma.j.cn115396-20210608-00213
- VernacularTitle:可切除性胰腺癌新辅助治疗的研究进展
- Author:
Gang ZHAO
1
;
Jianping GONG
;
Jinzheng LI
Author Information
1. 重庆市巫山县人民医院消化科 404700
- Keywords:
Pancreatic neoplasms;
Surgical procedures, operative;
Neoadjuvant therapy;
Stereotactic body radiation therapy
- From:
International Journal of Surgery
2021;48(12):843-848
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is highly malignant, and surgical resection is the only cure method at present. In recent years, neoadjuvant therapy has enabled some patients to be successfully downgraded with surgical treatment, which increased the R0 surgical resection rate and prolonged the survival time of patients, has become an important part in the treatment of pancreatic cancer. However, the applicability and standardization of neoadjuvant therapy for pancreatic cancer still need more advanced evidence. This article reviews whether neoadjuvant therapy should be used for resectable pancreatic cancer, the choice of neoadjuvant chemotherapy, and the progress, advantages and disadvantages of neoadjuvant chemoradiotherapy.
